This disclosure provides materials and methods for reducing production of virulence factors in C. perfringens and or other pathogenic clostridia with related Agr-like QS systems using compounds that interfere with the Agr-like quorum sensing (QS) system. For example, Agr-like QS system inhibitors based on peptidomimetic compounds of the Agr-like QS system signaling peptide (SP) or the SP receptor of C. perfringens, and methods of using the Agr-like QS system inhibitors to prevent, treat, or ameliorate a disease associated with C. perfringens infection are provided.

The disclosure relates to nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals. In particular, the disclosure relates to 5-nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals including bacterial, viral, parasitic or fungal infections. More particularly, the invention relates to metronidazole and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease caused by Clostridium species. Most preferably, the nitroimidazole is metronidazole administered in combination with berberine, or a berberine alkaloid, in a synergistic weight ratio of 1:1 or 1:2.

Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

A novel antimicrobial peptide is derived from myxinidin peptide. The novel antimicrobial peptides (i.e., myxinidin 2 and myxinidin 3) have low cytotoxicity for human cells while exhibiting an excellent antimicrobial activity, and exhibit an anti-inflammatory and a wound healing effect. Thus, they can be advantageously used as an effective ingredient of antibiotics, a cosmetic composition, a food additive, an animal feed additive, biopesticides, and a quasi-drug product or the like.

One aspect of the present invention relates to a method of inhibiting growth of Listeria monocytogenes on or in a product by applying an inhibitor compound of the formula: ##STR00001##
where the dashed lines are optional and represent a double bond or triple bond, and at least one of the dashed lines is present. Also disclosed is a method of inhibiting growth of Listeria monocytogenes on or in a subject by treating the subject with that compound. Further aspects of the present invention relate to pharmaceutical compositions, food product compositions, personal care product compositions, and cleaning product compositions comprising the subject inhibitor compounds.

The present disclosure relates to a novel Lactobacillus plantarum CJLP17 strain having acid resistance, bile resistance, and an immune-enhancing activity, and to a composition comprising the Lactobacillus plantarum CJLP17 strain.

A method of enhancing the growth of an animal, as well as treating or preventing antimicrobial infections is provided. The method includes causing the animal to ingest or absorb an effective amount of one or more Fe III complex compounds, including but not limited to Fe III complexes comprising ligands bound to the iron center such as amino acids or -hydroxy acids. The compounds are also useful for inhibiting, reducing, or preventing biofilm formation or buildup on a surface; the treatment of, inhibition of growth of, and inhibition of colonization by, bacteria, both in biological and non-biological environments; disinfecting surfaces, potentiating the effects of antibiotics and other anti-microbial agents, and increasing the sensitivity of bacteria and other microorganisms, to anti-microbial agents are also provided.